Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
| Glavni autor: | |
|---|---|
| Daljnji autori: | |
| Format: | Disertacija |
| Jezik: | English |
| Izdano: |
Brac University
2024
|
| Teme: | |
| Online pristup: | http://hdl.handle.net/10361/23954 |
| id |
10361-23954 |
|---|---|
| record_format |
dspace |
| spelling |
10361-239542024-09-01T21:05:23Z Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer Paul, Pulock Azam,Faruque Department of Pharmacy, Brac University Lung cancer Clinical trial Efficacy endpoints Targeted therapy Lungs--Cancer Clinical trials Chemotherapy This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. Cataloged from PDF version of thesis. Includes bibliographical references (pages 32-33). Researchers must prioritize non-small cell lung cancer clinical research due of its high mortality. Ongoing endeavors are being made to improve the accessibility, evaluation simplicity, and prediction accuracy of endpoints in clinical studies. In this study, we investigated the correlation of the primary endpoint overall survivals (OS) with overall response rate (ORR) and progression free survival (PFS). Also, the impact of performance status (PS) was examined through spearman rank correlation. The ORR, PFS, and OS all have a strong and significant positive relationship. Spearman correlation coefficient between OS and ORR, rs = 0.697 (p < 0.0001), OS and PFS, rs = 0.765 (p < 0.0001). Any change in ORR or PFS notably affects the OS. The PS did not correlate with the endpoints, indicating poor correlation. Therefore, a larger collection of clinical trials’ endpoints is needed to better understand the relationship between endpoints. Pulock Paul B. Pharmacy 2024-09-01T10:35:34Z 2024-09-01T10:35:34Z ©2023 2023-12 Thesis ID 19346040 http://hdl.handle.net/10361/23954 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 38 pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
English |
| topic |
Lung cancer Clinical trial Efficacy endpoints Targeted therapy Lungs--Cancer Clinical trials Chemotherapy |
| spellingShingle |
Lung cancer Clinical trial Efficacy endpoints Targeted therapy Lungs--Cancer Clinical trials Chemotherapy Paul, Pulock Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer |
| description |
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. |
| author2 |
Azam,Faruque |
| author_facet |
Azam,Faruque Paul, Pulock |
| format |
Thesis |
| author |
Paul, Pulock |
| author_sort |
Paul, Pulock |
| title |
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer |
| title_short |
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer |
| title_full |
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer |
| title_fullStr |
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer |
| title_full_unstemmed |
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer |
| title_sort |
effect of performance status on efficacy endpoints in phase ii trials of non-small cell lung cancer |
| publisher |
Brac University |
| publishDate |
2024 |
| url |
http://hdl.handle.net/10361/23954 |
| work_keys_str_mv |
AT paulpulock effectofperformancestatusonefficacyendpointsinphaseiitrialsofnonsmallcelllungcancer |
| _version_ |
1814309597440114688 |